Miguel Medina Padilla

This inventor holds 8 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 7 EPO patents. Top assignees: Noscira, S.a., Asd Therapeutics Partners, LLC, Neuropharma, S.a.. Active years: 2009-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Miguel Medina Padilla. Retrieved from https://idiyas.com/inventor/miguel-medina-padilla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 6)

% Patents Active = 75.0

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 9.0

ph-index = 3

Forward Citations = 32(Granted Patents)

Location History:

Tres Cantos, ES (2013)
Madrid, ES (2009 - 2014)
Tres-Cantos-Madrid, ES (2016)

Company Filing History:

Asd Therapeutics Partners, LLC

Instituto Biomar, S.a.

patents

where one patent can have more than one assignee

Years Active: 2009-2016

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9469618 - Thiadiazolidinediones as GSK-3 inhibitors (2016-10-18),

2. 9371299 - Thiadiazolidinediones as GSK-3 inhibitors (2016-06-21),

3. 8686042 - GSK-3 inhibitors (2014-04-01),

4. 8592446 - [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases (2013-11-26),

5. 8158661 - GSK-3 inhibitors (2012-04-17),

6. 8067441 - Use of collismycin and derivatives thereof as oxidative stress inhibitors (2011-11-29),

7. 7910739 - Acetylcholinesterase dual inhibitors (2011-03-22),

8. 7531561 - GSK-3 inhibitors (2009-05-12),

Title: **The Innovative Mind of Miguel Medina Padilla**

Introduction

Miguel Medina Padilla, a distinguished inventor based in Madrid, Spain, has made significant contributions to the field of pharmaceuticals through his innovative inventions. With a portfolio boasting six patents, he has created solutions targeting critical health issues.

Latest Patents

Among his most recent inventions are groundbreaking compounds designed to inhibit glycogen synthase kinase 3 (GSK-3), which plays a pivotal role in various diseases, including Alzheimer's disease and non-insulin dependent diabetes mellitus. His invention involves urea derivatives that serve as effective inhibitors of GSK-3, opening new avenues for treatment. Another notable innovation is a series of [1,10]-phenanthroline derivatives, aimed at treating neurodegenerative and hematological diseases. These compounds not only provide therapeutic benefits but are also included in new pharmaceutical compositions designed for ameliorating such conditions.

Career Highlights

Throughout his career, Miguel has worked with prominent companies in the pharmaceutical sector, including Noscira, S.A. and Neuropharma, S.A. His roles in these organizations have enabled him to harness his expertise and drive innovations that address pressing medical challenges.

Collaborations

In his professional journey, Miguel has collaborated with various talented individuals in the field, notably Ana Martinez Gil and Mercedes Alonso Cascon. These partnerships have fostered a fertile environment for the development of novel therapies and medical advancements.

Conclusion

Miguel Medina Padilla exemplifies the spirit of innovation in the pharmaceutical industry. His inventions not only contribute significantly to the scientific community but also have the potential to impact countless lives positively. As he continues to explore new frontiers, his work is a testament to the power of creativity and persistence in achieving significant breakthroughs in medicine.

Profile summary based on public USPTO records.